| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration, Artificial | 55 | 2024 | 424 | 8.450 |
Why?
|
| Critical Illness | 49 | 2025 | 346 | 7.300 |
Why?
|
| Intensive Care Units | 50 | 2025 | 460 | 6.580 |
Why?
|
| Hypnotics and Sedatives | 27 | 2024 | 142 | 4.760 |
Why?
|
| Conscious Sedation | 22 | 2024 | 78 | 4.400 |
Why?
|
| Early Ambulation | 10 | 2023 | 31 | 3.680 |
Why?
|
| Respiratory Insufficiency | 14 | 2024 | 205 | 3.370 |
Why?
|
| Delirium | 18 | 2018 | 79 | 3.280 |
Why?
|
| Noninvasive Ventilation | 10 | 2022 | 42 | 3.230 |
Why?
|
| Critical Care | 27 | 2023 | 447 | 2.520 |
Why?
|
| Muscle Weakness | 7 | 2018 | 67 | 2.070 |
Why?
|
| Sepsis | 10 | 2020 | 391 | 1.860 |
Why?
|
| Propofol | 10 | 2024 | 95 | 1.660 |
Why?
|
| Ventilator Weaning | 9 | 2017 | 40 | 1.640 |
Why?
|
| Physical Therapy Modalities | 8 | 2021 | 93 | 1.580 |
Why?
|
| Analgesia | 7 | 2020 | 64 | 1.380 |
Why?
|
| Shock, Septic | 5 | 2023 | 125 | 1.130 |
Why?
|
| Humans | 132 | 2025 | 96114 | 1.110 |
Why?
|
| Pain | 8 | 2018 | 426 | 1.090 |
Why?
|
| Masks | 3 | 2018 | 31 | 1.010 |
Why?
|
| Vasoconstrictor Agents | 3 | 2018 | 68 | 0.980 |
Why?
|
| Intubation | 2 | 2017 | 23 | 0.950 |
Why?
|
| Head Protective Devices | 4 | 2023 | 23 | 0.950 |
Why?
|
| Length of Stay | 18 | 2022 | 833 | 0.930 |
Why?
|
| Occupational Therapy | 4 | 2018 | 17 | 0.880 |
Why?
|
| Polyneuropathies | 2 | 2014 | 26 | 0.840 |
Why?
|
| Benzodiazepines | 5 | 2016 | 71 | 0.830 |
Why?
|
| Intubation, Intratracheal | 4 | 2021 | 161 | 0.820 |
Why?
|
| Fentanyl | 2 | 2014 | 87 | 0.810 |
Why?
|
| Deep Sedation | 4 | 2018 | 19 | 0.770 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2023 | 56 | 0.770 |
Why?
|
| Male | 60 | 2025 | 45872 | 0.750 |
Why?
|
| Aged | 42 | 2025 | 20973 | 0.750 |
Why?
|
| Middle Aged | 53 | 2025 | 28372 | 0.740 |
Why?
|
| Hematologic Neoplasms | 3 | 2016 | 372 | 0.720 |
Why?
|
| Respiratory Dead Space | 1 | 2021 | 4 | 0.720 |
Why?
|
| Midazolam | 4 | 2009 | 49 | 0.710 |
Why?
|
| Female | 60 | 2025 | 50046 | 0.700 |
Why?
|
| Airway Extubation | 3 | 2018 | 16 | 0.690 |
Why?
|
| Neuromuscular Blocking Agents | 3 | 2023 | 28 | 0.690 |
Why?
|
| Immunocompromised Host | 3 | 2018 | 147 | 0.680 |
Why?
|
| Statistics as Topic | 1 | 2021 | 236 | 0.660 |
Why?
|
| Carbon Dioxide | 1 | 2021 | 212 | 0.660 |
Why?
|
| Adult | 48 | 2024 | 28725 | 0.650 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 192 | 0.630 |
Why?
|
| Dexmedetomidine | 2 | 2010 | 18 | 0.610 |
Why?
|
| Psychomotor Agitation | 5 | 2018 | 31 | 0.570 |
Why?
|
| Laryngeal Masks | 1 | 2018 | 13 | 0.570 |
Why?
|
| Analgesics | 2 | 2009 | 132 | 0.560 |
Why?
|
| Lidocaine | 1 | 2018 | 67 | 0.550 |
Why?
|
| Analgesics, Opioid | 4 | 2012 | 513 | 0.540 |
Why?
|
| Immobilization | 2 | 2014 | 22 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 4 | 2013 | 1096 | 0.530 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 84 | 0.530 |
Why?
|
| Lung Injury | 1 | 2017 | 60 | 0.520 |
Why?
|
| Bacteremia | 4 | 2020 | 108 | 0.510 |
Why?
|
| Survivors | 3 | 2012 | 204 | 0.500 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2022 | 67 | 0.500 |
Why?
|
| Positive-Pressure Respiration | 6 | 2021 | 50 | 0.490 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 34 | 0.490 |
Why?
|
| Staphylococcal Infections | 3 | 2020 | 289 | 0.490 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2016 | 26 | 0.470 |
Why?
|
| Lorazepam | 3 | 2010 | 14 | 0.460 |
Why?
|
| Pain Management | 5 | 2020 | 179 | 0.450 |
Why?
|
| Catheterization, Central Venous | 3 | 2015 | 120 | 0.440 |
Why?
|
| Vasopressins | 2 | 2013 | 50 | 0.440 |
Why?
|
| Logistic Models | 7 | 2021 | 1268 | 0.430 |
Why?
|
| Hyperglycemia | 2 | 2018 | 181 | 0.430 |
Why?
|
| Ventilators, Mechanical | 2 | 2013 | 43 | 0.430 |
Why?
|
| Acute Lung Injury | 1 | 2014 | 68 | 0.420 |
Why?
|
| Hemorrhage | 1 | 2016 | 294 | 0.410 |
Why?
|
| Immune System Diseases | 1 | 2014 | 28 | 0.410 |
Why?
|
| Thoracic Diseases | 2 | 2007 | 28 | 0.410 |
Why?
|
| Humidity | 1 | 2013 | 94 | 0.400 |
Why?
|
| ROC Curve | 5 | 2021 | 797 | 0.380 |
Why?
|
| Norepinephrine | 1 | 2013 | 174 | 0.380 |
Why?
|
| Physical Examination | 2 | 2006 | 154 | 0.370 |
Why?
|
| Exercise | 2 | 2014 | 354 | 0.370 |
Why?
|
| Pain Measurement | 5 | 2018 | 378 | 0.370 |
Why?
|
| Staphylococcus aureus | 2 | 2018 | 287 | 0.360 |
Why?
|
| Long-Term Care | 1 | 2012 | 63 | 0.360 |
Why?
|
| Treatment Outcome | 10 | 2023 | 9177 | 0.360 |
Why?
|
| Tracheotomy | 1 | 2011 | 18 | 0.340 |
Why?
|
| Health Services Research | 1 | 2012 | 148 | 0.340 |
Why?
|
| Time Factors | 11 | 2021 | 5585 | 0.340 |
Why?
|
| Biomedical Research | 2 | 2014 | 441 | 0.340 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 180 | 0.340 |
Why?
|
| Retrospective Studies | 15 | 2021 | 10288 | 0.310 |
Why?
|
| Anxiety | 3 | 2013 | 339 | 0.310 |
Why?
|
| Risk Factors | 10 | 2016 | 5961 | 0.310 |
Why?
|
| Neuromuscular Diseases | 1 | 2009 | 30 | 0.310 |
Why?
|
| Recovery of Function | 1 | 2011 | 348 | 0.300 |
Why?
|
| GABA Modulators | 1 | 2009 | 8 | 0.300 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2009 | 34 | 0.300 |
Why?
|
| Quality Improvement | 1 | 2013 | 502 | 0.290 |
Why?
|
| Pneumonia | 3 | 2022 | 197 | 0.290 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 682 | 0.290 |
Why?
|
| Neck | 1 | 2009 | 99 | 0.290 |
Why?
|
| Exercise Therapy | 1 | 2009 | 94 | 0.290 |
Why?
|
| Wakefulness | 4 | 2010 | 138 | 0.280 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 60 | 0.270 |
Why?
|
| Societies, Medical | 1 | 2012 | 644 | 0.270 |
Why?
|
| Pulmonary Edema | 1 | 2008 | 54 | 0.270 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 901 | 0.270 |
Why?
|
| Quality of Life | 4 | 2023 | 1816 | 0.260 |
Why?
|
| Prospective Studies | 10 | 2025 | 4672 | 0.260 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 37 | 0.260 |
Why?
|
| Etomidate | 1 | 2007 | 11 | 0.260 |
Why?
|
| Sleep Wake Disorders | 2 | 2018 | 128 | 0.260 |
Why?
|
| Adrenal Glands | 1 | 2007 | 78 | 0.260 |
Why?
|
| Anesthetics, Intravenous | 1 | 2007 | 43 | 0.250 |
Why?
|
| Central Venous Pressure | 1 | 2006 | 28 | 0.250 |
Why?
|
| Prognosis | 6 | 2016 | 4030 | 0.250 |
Why?
|
| Hospital Mortality | 5 | 2018 | 483 | 0.250 |
Why?
|
| Thoracotomy | 1 | 2007 | 68 | 0.250 |
Why?
|
| Muscle Strength | 2 | 2018 | 38 | 0.250 |
Why?
|
| Respiratory Paralysis | 1 | 2006 | 9 | 0.250 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 232 | 0.250 |
Why?
|
| Jugular Veins | 1 | 2006 | 73 | 0.250 |
Why?
|
| Endosonography | 1 | 2007 | 101 | 0.240 |
Why?
|
| Hypercapnia | 1 | 2006 | 49 | 0.240 |
Why?
|
| APACHE | 4 | 2016 | 24 | 0.240 |
Why?
|
| United States | 11 | 2024 | 7768 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 514 | 0.240 |
Why?
|
| Patient-Centered Care | 1 | 2008 | 228 | 0.240 |
Why?
|
| Myocardial Ischemia | 1 | 2007 | 167 | 0.230 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2006 | 81 | 0.230 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 341 | 0.230 |
Why?
|
| Myeloproliferative Disorders | 1 | 2007 | 145 | 0.230 |
Why?
|
| Chicago | 4 | 2021 | 1506 | 0.230 |
Why?
|
| Metabolome | 1 | 2025 | 63 | 0.220 |
Why?
|
| Oxygen | 4 | 2022 | 788 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2021 | 3110 | 0.210 |
Why?
|
| Algorithms | 5 | 2016 | 2016 | 0.210 |
Why?
|
| Single-Blind Method | 3 | 2014 | 162 | 0.210 |
Why?
|
| Infusions, Intravenous | 5 | 2012 | 423 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 381 | 0.200 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2003 | 53 | 0.200 |
Why?
|
| Feces | 1 | 2025 | 360 | 0.200 |
Why?
|
| Lymph Nodes | 1 | 2007 | 565 | 0.200 |
Why?
|
| Immunity | 2 | 2022 | 157 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 3927 | 0.190 |
Why?
|
| Blood Glucose | 2 | 2018 | 873 | 0.190 |
Why?
|
| Terminal Care | 1 | 2004 | 146 | 0.190 |
Why?
|
| Respiratory Mechanics | 1 | 2023 | 114 | 0.190 |
Why?
|
| Helium | 1 | 2002 | 13 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2006 | 354 | 0.180 |
Why?
|
| Plant Leaves | 2 | 2020 | 88 | 0.180 |
Why?
|
| Albuterol | 1 | 2002 | 35 | 0.180 |
Why?
|
| Narcotics | 1 | 2002 | 72 | 0.180 |
Why?
|
| Diaphragm | 1 | 2022 | 75 | 0.180 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 394 | 0.180 |
Why?
|
| Restraint, Physical | 2 | 2018 | 32 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 813 | 0.180 |
Why?
|
| Validation Studies as Topic | 1 | 2021 | 20 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2003 | 125 | 0.180 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 311 | 0.170 |
Why?
|
| Oxygen Consumption | 2 | 1999 | 257 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2014 | 1546 | 0.170 |
Why?
|
| Pandemics | 3 | 2023 | 880 | 0.170 |
Why?
|
| Plant Extracts | 2 | 2020 | 248 | 0.160 |
Why?
|
| Adolescent | 3 | 2023 | 9895 | 0.160 |
Why?
|
| Body Temperature | 1 | 2020 | 131 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2020 | 71 | 0.160 |
Why?
|
| Justicia | 1 | 2020 | 1 | 0.160 |
Why?
|
| Antibody Formation | 1 | 2020 | 181 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 216 | 0.160 |
Why?
|
| Work of Breathing | 1 | 1999 | 7 | 0.160 |
Why?
|
| Bed Rest | 2 | 2009 | 5 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2000 | 65 | 0.150 |
Why?
|
| Endocardium | 1 | 2000 | 99 | 0.150 |
Why?
|
| Heart Arrest | 2 | 2014 | 312 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 458 | 0.150 |
Why?
|
| Oxyhemoglobins | 1 | 1999 | 33 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2003 | 463 | 0.150 |
Why?
|
| Hematopoiesis | 1 | 2020 | 183 | 0.150 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2000 | 139 | 0.150 |
Why?
|
| Oximetry | 1 | 1999 | 91 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 348 | 0.140 |
Why?
|
| Laryngeal Edema | 1 | 2018 | 7 | 0.140 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 22 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2000 | 249 | 0.140 |
Why?
|
| Pain Perception | 1 | 2018 | 19 | 0.140 |
Why?
|
| Patients' Rooms | 2 | 2014 | 14 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 7230 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 590 | 0.140 |
Why?
|
| Sarcoma | 1 | 2000 | 225 | 0.140 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 134 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 42 | 0.140 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 105 | 0.140 |
Why?
|
| Clinical Protocols | 4 | 2017 | 162 | 0.140 |
Why?
|
| Overweight | 1 | 2018 | 121 | 0.130 |
Why?
|
| Plant Vascular Bundle | 1 | 2017 | 1 | 0.130 |
Why?
|
| Zingiberaceae | 1 | 2017 | 10 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2018 | 117 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Population Groups | 1 | 2017 | 42 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 155 | 0.130 |
Why?
|
| Resuscitation | 2 | 2013 | 131 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 1179 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 1999 | 150 | 0.130 |
Why?
|
| Neurologic Examination | 1 | 1997 | 130 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 15 | 0.120 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 82 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 1999 | 247 | 0.120 |
Why?
|
| Point-of-Care Testing | 1 | 2016 | 28 | 0.120 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 109 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 2017 | 132 | 0.120 |
Why?
|
| Skin Ulcer | 1 | 2016 | 27 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 2463 | 0.120 |
Why?
|
| Age Factors | 3 | 2016 | 1963 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 935 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 49 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2016 | 40 | 0.120 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 30 | 0.120 |
Why?
|
| Equipment Design | 1 | 2016 | 427 | 0.120 |
Why?
|
| Self-Injurious Behavior | 1 | 2017 | 115 | 0.110 |
Why?
|
| Central Venous Catheters | 1 | 2015 | 22 | 0.110 |
Why?
|
| Physicians | 1 | 2022 | 707 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Butyrophenones | 2 | 2006 | 5 | 0.110 |
Why?
|
| Medicaid | 1 | 2018 | 260 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2017 | 437 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 458 | 0.110 |
Why?
|
| Urban Population | 2 | 2014 | 240 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.110 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2014 | 54 | 0.100 |
Why?
|
| Asthma | 1 | 2002 | 1051 | 0.100 |
Why?
|
| Interactive Ventilatory Support | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 119 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 317 | 0.100 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2013 | 33 | 0.100 |
Why?
|
| Respiratory Rate | 1 | 2013 | 25 | 0.100 |
Why?
|
| Insulin | 2 | 2018 | 1190 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1981 | 0.100 |
Why?
|
| Administration, Inhalation | 2 | 2024 | 203 | 0.100 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2012 | 4 | 0.100 |
Why?
|
| Leukemic Infiltration | 1 | 2012 | 14 | 0.100 |
Why?
|
| Conjunctival Diseases | 1 | 2012 | 6 | 0.100 |
Why?
|
| Arterial Pressure | 1 | 2013 | 43 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2012 | 37 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2011 | 2040 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 257 | 0.100 |
Why?
|
| Cytokines | 3 | 2023 | 872 | 0.090 |
Why?
|
| Erythema | 1 | 2012 | 33 | 0.090 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 238 | 0.090 |
Why?
|
| Professional Role | 1 | 2012 | 42 | 0.090 |
Why?
|
| Neoplasms | 2 | 2016 | 3248 | 0.090 |
Why?
|
| Family Health | 1 | 2012 | 159 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1973 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2014 | 382 | 0.090 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 19 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 422 | 0.090 |
Why?
|
| Young Adult | 2 | 2014 | 7025 | 0.090 |
Why?
|
| Obesity | 1 | 2018 | 1034 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2012 | 161 | 0.090 |
Why?
|
| Work | 1 | 2011 | 15 | 0.090 |
Why?
|
| Phylogeny | 1 | 2017 | 1275 | 0.090 |
Why?
|
| Research Design | 1 | 2014 | 631 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 995 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2014 | 413 | 0.080 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 392 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2004 | 246 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2012 | 307 | 0.080 |
Why?
|
| Patient Discharge | 2 | 2011 | 361 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2011 | 245 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 22 | 0.080 |
Why?
|
| Communication | 2 | 2004 | 477 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1619 | 0.080 |
Why?
|
| Iowa | 1 | 2009 | 35 | 0.080 |
Why?
|
| Mobility Limitation | 1 | 2009 | 20 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 2 | 1999 | 271 | 0.070 |
Why?
|
| Tidal Volume | 1 | 2008 | 61 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2009 | 171 | 0.070 |
Why?
|
| Inhalation | 1 | 2008 | 34 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2006 | 1808 | 0.070 |
Why?
|
| Decision Trees | 2 | 2008 | 63 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 64 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 647 | 0.070 |
Why?
|
| Thrombocythemia, Essential | 1 | 2007 | 16 | 0.070 |
Why?
|
| Platelet Count | 1 | 2007 | 97 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2009 | 744 | 0.060 |
Why?
|
| Evidence-Based Emergency Medicine | 2 | 2016 | 2 | 0.060 |
Why?
|
| Medical Staff | 1 | 2006 | 10 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 884 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2012 | 854 | 0.060 |
Why?
|
| HIV Infections | 1 | 2016 | 974 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 220 | 0.060 |
Why?
|
| Catheterization | 1 | 2007 | 238 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 69 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 3581 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2006 | 128 | 0.060 |
Why?
|
| Cognition | 1 | 2010 | 635 | 0.060 |
Why?
|
| Observer Variation | 3 | 2014 | 626 | 0.060 |
Why?
|
| Cardiac Catheterization | 1 | 2007 | 330 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2007 | 300 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 514 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 294 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2018 | 713 | 0.060 |
Why?
|
| Metabolomics | 1 | 2025 | 98 | 0.050 |
Why?
|
| Barotrauma | 1 | 2004 | 3 | 0.050 |
Why?
|
| Thrombosis | 1 | 2007 | 326 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2004 | 51 | 0.050 |
Why?
|
| Lung | 1 | 2011 | 1384 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2025 | 91 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2004 | 47 | 0.050 |
Why?
|
| Cholestasis | 1 | 2004 | 44 | 0.050 |
Why?
|
| Isoflurane | 1 | 2024 | 69 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 89 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2011 | 909 | 0.050 |
Why?
|
| Anesthetics, Inhalation | 1 | 2024 | 102 | 0.050 |
Why?
|
| Goals | 1 | 2004 | 68 | 0.050 |
Why?
|
| Psychology | 1 | 2003 | 26 | 0.050 |
Why?
|
| Mental Processes | 1 | 2003 | 32 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2004 | 120 | 0.050 |
Why?
|
| Time | 1 | 2003 | 79 | 0.050 |
Why?
|
| Hospital Records | 1 | 2003 | 4 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2007 | 929 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2004 | 128 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 873 | 0.050 |
Why?
|
| Proxy | 1 | 2003 | 27 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 36 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 231 | 0.050 |
Why?
|
| Status Asthmaticus | 1 | 2002 | 9 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1349 | 0.050 |
Why?
|
| Paralysis | 1 | 2022 | 34 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 77 | 0.050 |
Why?
|
| Spirometry | 1 | 2002 | 78 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 132 | 0.050 |
Why?
|
| District of Columbia | 1 | 2021 | 19 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2002 | 137 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2002 | 95 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2002 | 214 | 0.040 |
Why?
|
| Sinusitis | 1 | 2004 | 223 | 0.040 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2002 | 62 | 0.040 |
Why?
|
| Emergencies | 1 | 2002 | 124 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 2086 | 0.040 |
Why?
|
| Cannula | 1 | 2021 | 57 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 136 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 2883 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 125 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 75 | 0.040 |
Why?
|
| Hospitalization | 2 | 2018 | 943 | 0.040 |
Why?
|
| Informed Consent | 1 | 2003 | 281 | 0.040 |
Why?
|
| Erythrocyte Indices | 1 | 2020 | 9 | 0.040 |
Why?
|
| Phytochemicals | 1 | 2020 | 6 | 0.040 |
Why?
|
| Fever | 1 | 2020 | 131 | 0.040 |
Why?
|
| Brain | 1 | 2010 | 2482 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 169 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 370 | 0.040 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1999 | 18 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 163 | 0.040 |
Why?
|
| Hemoglobin, Sickle | 1 | 1999 | 17 | 0.040 |
Why?
|
| Morphine | 1 | 2000 | 130 | 0.040 |
Why?
|
| Hospitals, University | 1 | 1999 | 199 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2020 | 196 | 0.040 |
Why?
|
| Auscultation | 1 | 1999 | 5 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 206 | 0.040 |
Why?
|
| Neutropenia | 1 | 1999 | 218 | 0.040 |
Why?
|
| Palpation | 1 | 1999 | 19 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 311 | 0.040 |
Why?
|
| Skin | 1 | 2002 | 605 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 819 | 0.040 |
Why?
|
| Anemia | 1 | 2020 | 137 | 0.040 |
Why?
|
| Food, Formulated | 1 | 2018 | 25 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2018 | 31 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 294 | 0.040 |
Why?
|
| Dietary Carbohydrates | 1 | 2018 | 39 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 25 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 481 | 0.040 |
Why?
|
| Energy Intake | 1 | 2018 | 100 | 0.040 |
Why?
|
| Syndrome | 1 | 1999 | 453 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2018 | 39 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1999 | 257 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 102 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 580 | 0.030 |
Why?
|
| Lymphoma | 1 | 1999 | 271 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 1010 | 0.030 |
Why?
|
| Patient Admission | 1 | 1998 | 122 | 0.030 |
Why?
|
| Leukemia | 1 | 1999 | 328 | 0.030 |
Why?
|
| Xylem | 1 | 2017 | 1 | 0.030 |
Why?
|
| Curcuma | 1 | 2017 | 2 | 0.030 |
Why?
|
| Rhizome | 1 | 2017 | 7 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2018 | 97 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 171 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2018 | 151 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2017 | 48 | 0.030 |
Why?
|
| Acute Disease | 1 | 1999 | 872 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2017 | 143 | 0.030 |
Why?
|
| Magnoliopsida | 1 | 2017 | 26 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1998 | 198 | 0.030 |
Why?
|
| Thorax | 1 | 2017 | 80 | 0.030 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 76 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2017 | 116 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 594 | 0.030 |
Why?
|
| Plant Roots | 1 | 2017 | 113 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 728 | 0.030 |
Why?
|
| Hypoxia | 1 | 2021 | 682 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2000 | 475 | 0.030 |
Why?
|
| Body Mass Index | 1 | 1999 | 815 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1998 | 418 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 67 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 3 | 0.030 |
Why?
|
| Bronchitis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Tracheitis | 1 | 2015 | 3 | 0.030 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2015 | 11 | 0.030 |
Why?
|
| Adrenal Insufficiency | 1 | 2015 | 24 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 1985 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2537 | 0.030 |
Why?
|
| Species Specificity | 1 | 2017 | 707 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 72 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2015 | 60 | 0.030 |
Why?
|
| Malnutrition | 1 | 2015 | 36 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 350 | 0.030 |
Why?
|
| Neural Conduction | 1 | 2014 | 72 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 1998 | 514 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 85 | 0.030 |
Why?
|
| Heart Ventricles | 1 | 2000 | 810 | 0.030 |
Why?
|
| Communication Barriers | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 12541 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 1267 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 201 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 296 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1958 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 2778 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 157 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2000 | 1201 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1996 | 505 | 0.020 |
Why?
|
| Psychometrics | 1 | 2014 | 340 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1999 | 793 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2016 | 298 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 599 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 304 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1010 | 0.020 |
Why?
|
| American Heart Association | 1 | 2011 | 110 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 363 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 342 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2011 | 46 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1715 | 0.020 |
Why?
|
| Rats | 1 | 2017 | 4155 | 0.020 |
Why?
|
| Animals | 3 | 2020 | 28919 | 0.020 |
Why?
|
| Disease Management | 1 | 2013 | 360 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2011 | 121 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2011 | 110 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 438 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2550 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3490 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 522 | 0.020 |
Why?
|
| Inpatients | 1 | 2011 | 347 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 1988 | 100 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1988 | 111 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 147 | 0.020 |
Why?
|
| Respiration | 1 | 2008 | 281 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 501 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 2480 | 0.010 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2002 | 15 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 2860 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 210 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 297 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2011 | 1134 | 0.010 |
Why?
|
| Illinois | 1 | 2002 | 531 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 296 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 378 | 0.010 |
Why?
|
| Vegetables | 1 | 1999 | 50 | 0.010 |
Why?
|
| Fruit | 1 | 1999 | 81 | 0.010 |
Why?
|
| Total Quality Management | 1 | 1998 | 34 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 386 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1999 | 491 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1564 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2781 | 0.000 |
Why?
|
| Angiography | 1 | 1988 | 209 | 0.000 |
Why?
|
| Leg | 1 | 1988 | 143 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1988 | 202 | 0.000 |
Why?
|